Merck & Co.’s drug indicated as a monotherapy and as an add-on to either metformin or TZDs. Merck & Co.’s Januvia™ (sitagliptin phosphate), which the company says is the first and only DPP-4 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results